vs
美敦力（MDT）与RYDER SYSTEM INC（R）财务数据对比。点击上方公司名可切换其他公司
RYDER SYSTEM INC的季度营收约是美敦力的1.5倍（$13.1B vs $9.0B），美敦力净利率更高（15.3% vs 0.7%，领先14.6%），美敦力同比增速更快（6.6% vs 1.0%），美敦力自由现金流更多（$457.0M vs $273.0M），过去两年RYDER SYSTEM INC的营收复合增速更高（102.9% vs 5.3%）
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
Ryder System Inc.是美国专业运输物流服务商，总部位于佛罗里达州科勒尔盖布尔斯，业务覆盖美国及英国，核心业务包含卡车租赁、车队管理、供应链及运输管理，同时提供车辆维保、二手车销售、专业司机派遣、电商履约与最后一公里配送等多元服务。
MDT vs R — 直观对比
营收规模更大
R
是对方的1.5倍
$9.0B
营收增速更快
MDT
高出5.6%
1.0%
净利率更高
MDT
高出14.6%
0.7%
自由现金流更多
MDT
多$184.0M
$273.0M
两年增速更快
R
近两年复合增速
5.3%
损益表 — Q2 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.0B | $13.1B |
| 净利润 | $1.4B | $93.0M |
| 毛利率 | 65.8% | — |
| 营业利润率 | 18.8% | — |
| 净利率 | 15.3% | 0.7% |
| 营收同比 | 6.6% | 1.0% |
| 净利润同比 | 8.2% | -5.1% |
| 每股收益（稀释后） | $1.07 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDTR
| Q1 26 | — | $13.1B | ||
| Q4 25 | $9.0B | $3.2B | ||
| Q3 25 | $8.6B | $3.2B | ||
| Q2 25 | $8.9B | $3.2B | ||
| Q1 25 | $8.3B | $3.1B | ||
| Q4 24 | $8.4B | $3.2B | ||
| Q3 24 | $7.9B | $3.2B | ||
| Q2 24 | $8.6B | $3.2B |
净利润MDTR
| Q1 26 | — | $93.0M | ||
| Q4 25 | $1.4B | $132.0M | ||
| Q3 25 | $1.0B | $138.0M | ||
| Q2 25 | $1.1B | $131.0M | ||
| Q1 25 | $1.3B | $98.0M | ||
| Q4 24 | $1.3B | $135.0M | ||
| Q3 24 | $1.0B | $142.0M | ||
| Q2 24 | $654.0M | $127.0M |
毛利率MDTR
| Q1 26 | — | — | ||
| Q4 25 | 65.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 64.8% | — | ||
| Q1 25 | 66.5% | — | ||
| Q4 24 | 64.9% | — | ||
| Q3 24 | 65.1% | — | ||
| Q2 24 | 64.5% | — |
营业利润率MDTR
| Q1 26 | — | — | ||
| Q4 25 | 18.8% | 5.6% | ||
| Q3 25 | 16.8% | 6.0% | ||
| Q2 25 | 16.1% | 5.8% | ||
| Q1 25 | 19.9% | 4.3% | ||
| Q4 24 | 19.0% | 5.7% | ||
| Q3 24 | 16.1% | 5.9% | ||
| Q2 24 | 12.3% | 5.6% |
净利率MDTR
| Q1 26 | — | 0.7% | ||
| Q4 25 | 15.3% | 4.2% | ||
| Q3 25 | 12.1% | 4.4% | ||
| Q2 25 | 11.8% | 4.1% | ||
| Q1 25 | 15.6% | 3.1% | ||
| Q4 24 | 15.1% | 4.2% | ||
| Q3 24 | 13.2% | 4.5% | ||
| Q2 24 | 7.6% | 4.0% |
每股收益（稀释后）MDTR
| Q1 26 | — | $2.34 | ||
| Q4 25 | $1.07 | $3.22 | ||
| Q3 25 | $0.81 | $3.32 | ||
| Q2 25 | $0.81 | $3.13 | ||
| Q1 25 | $1.01 | $2.27 | ||
| Q4 24 | $0.99 | $3.09 | ||
| Q3 24 | $0.80 | $3.24 | ||
| Q2 24 | $0.50 | $2.84 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3B | $182.0M |
| 总债务越低越好 | $27.7B | — |
| 股东权益账面价值 | $48.7B | $2.9B |
| 总资产 | $91.3B | — |
| 负债/权益比越低杠杆越低 | 0.57× | — |
8季度趋势，按日历期对齐
现金及短期投资MDTR
| Q1 26 | — | $182.0M | ||
| Q4 25 | $8.3B | $198.0M | ||
| Q3 25 | $8.1B | $189.0M | ||
| Q2 25 | $9.0B | $180.0M | ||
| Q1 25 | $7.9B | $151.0M | ||
| Q4 24 | $8.0B | $154.0M | ||
| Q3 24 | $7.8B | $162.0M | ||
| Q2 24 | $8.0B | $164.0M |
总债务MDTR
| Q1 26 | — | — | ||
| Q4 25 | $27.7B | $6.8B | ||
| Q3 25 | $26.2B | $7.3B | ||
| Q2 25 | $25.6B | $7.0B | ||
| Q1 25 | $24.0B | $6.7B | ||
| Q4 24 | $24.6B | $6.7B | ||
| Q3 24 | $26.3B | $6.6B | ||
| Q2 24 | $23.9B | $6.5B |
股东权益MDTR
| Q1 26 | — | $2.9B | ||
| Q4 25 | $48.7B | $3.1B | ||
| Q3 25 | $47.9B | $3.1B | ||
| Q2 25 | $48.0B | $3.1B | ||
| Q1 25 | $49.4B | $3.0B | ||
| Q4 24 | $48.5B | $3.1B | ||
| Q3 24 | $47.9B | $3.1B | ||
| Q2 24 | $50.2B | $3.1B |
总资产MDTR
| Q1 26 | — | — | ||
| Q4 25 | $91.3B | $16.4B | ||
| Q3 25 | $91.0B | $16.5B | ||
| Q2 25 | $91.7B | $16.5B | ||
| Q1 25 | $90.0B | $16.4B | ||
| Q4 24 | $90.0B | $16.7B | ||
| Q3 24 | $89.7B | $16.5B | ||
| Q2 24 | $90.0B | $16.4B |
负债/权益比MDTR
| Q1 26 | — | — | ||
| Q4 25 | 0.57× | 2.24× | ||
| Q3 25 | 0.55× | 2.35× | ||
| Q2 25 | 0.53× | 2.27× | ||
| Q1 25 | 0.49× | 2.21× | ||
| Q4 24 | 0.51× | 2.14× | ||
| Q3 24 | 0.55× | 2.17× | ||
| Q2 24 | 0.48× | 2.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $925.0M | $583.0M |
| 自由现金流经营现金流 - 资本支出 | $457.0M | $273.0M |
| 自由现金流率自由现金流/营收 | 5.1% | 2.1% |
| 资本支出强度资本支出/营收 | 5.2% | 3.3% |
| 现金转化率经营现金流/净利润 | 0.67× | 6.27× |
| 过去12个月自由现金流最近4个季度 | $5.2B | $595.0M |
8季度趋势，按日历期对齐
经营现金流MDTR
| Q1 26 | — | $583.0M | ||
| Q4 25 | $925.0M | $749.0M | ||
| Q3 25 | $1.1B | $442.0M | ||
| Q2 25 | $2.5B | $752.0M | ||
| Q1 25 | $2.6B | $651.0M | ||
| Q4 24 | $958.0M | $558.0M | ||
| Q3 24 | $986.0M | $629.0M | ||
| Q2 24 | $2.8B | $552.0M |
自由现金流MDTR
| Q1 26 | — | $273.0M | ||
| Q4 25 | $457.0M | $344.0M | ||
| Q3 25 | $584.0M | $-85.0M | ||
| Q2 25 | $2.1B | $63.0M | ||
| Q1 25 | $2.1B | $137.0M | ||
| Q4 24 | $554.0M | $-201.0M | ||
| Q3 24 | $466.0M | $30.0M | ||
| Q2 24 | $2.4B | $-87.0M |
自由现金流率MDTR
| Q1 26 | — | 2.1% | ||
| Q4 25 | 5.1% | 10.8% | ||
| Q3 25 | 6.8% | -2.7% | ||
| Q2 25 | 23.2% | 2.0% | ||
| Q1 25 | 25.3% | 4.4% | ||
| Q4 24 | 6.6% | -6.3% | ||
| Q3 24 | 5.9% | 0.9% | ||
| Q2 24 | 27.4% | -2.7% |
资本支出强度MDTR
| Q1 26 | — | 3.3% | ||
| Q4 25 | 5.2% | 12.8% | ||
| Q3 25 | 5.9% | 16.6% | ||
| Q2 25 | 5.1% | 21.6% | ||
| Q1 25 | 5.7% | 16.4% | ||
| Q4 24 | 4.8% | 23.8% | ||
| Q3 24 | 6.6% | 18.9% | ||
| Q2 24 | 5.0% | 20.1% |
现金转化率MDTR
| Q1 26 | — | 6.27× | ||
| Q4 25 | 0.67× | 5.67× | ||
| Q3 25 | 1.05× | 3.20× | ||
| Q2 25 | 2.39× | 5.74× | ||
| Q1 25 | 1.99× | 6.64× | ||
| Q4 24 | 0.75× | 4.13× | ||
| Q3 24 | 0.95× | 4.43× | ||
| Q2 24 | 4.25× | 4.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDT
| Cardiac Rhythm And Heart Failure Division | $1.8B | 20% |
| Surgical Endoscopy | $1.7B | 19% |
| Other | $1.3B | 14% |
| Structural Heart And Aortic Division | $956.0M | 11% |
| Diabetes Group | $757.0M | 8% |
| Specialty Therapies Division | $744.0M | 8% |
| Coronary And Peripheral Vascular Division | $655.0M | 7% |
| Neuromodulation Division | $520.0M | 6% |
| Acute Care Monitoring | $493.0M | 6% |
| IE | $35.0M | 0% |
R
暂无分部数据
